Table 1.
The patients’ clinicopathological characteristics.
| Patients (n = 76) Levels of Exosomes | ||||
|---|---|---|---|---|
| Parameters | n (%) | Low | High | p Value |
| Age (years) | Median 65 (range, 44–84) | 0.037 | ||
| <65 | 38 (50) | 12 | 22 | |
| ≥65 | 38 (50) | 26 | 16 | |
| Gender | 0.544 | |||
| Male | 63 (82.9) | 30 | 33 | |
| Female | 13 (17.1) | 8 | 5 | |
| Stage | 0.318 | |||
| Stage IIIA/B | 23 (30.3) | 14 | 9 | |
| Stage IV | 53 (69.7) | 24 | 29 | |
| Histology | 0.100 | |||
| Squamous | 37 (48.7) | 19 | 18 | |
| Non-squamous | 39 (51.3) | 19 | 20 | |
| EGFR status | 0.484 | |||
| Wild-type | 30 (39.5) | 16 | 14 | |
| Mutant | 2 (2.6) | 0 | 2 | |
| NE | 44 (57.9) | 22 | 22 | |
| Platinum-based chemotherapy regimen | 0.725 | |||
| Taxanes | 35 (47.9) | 18 | 17 | |
| Pemetrexed | 18 (24.7) | 8 | 10 | |
| Gemcitabine | 18 (24.7) | 10 | 8 | |
| Vinorelbine | 2 (2.7) | 1 | 1 | |
| Response to therapy (after 3 cycles) | 0.001 | |||
| PR | 19 (25) | 14 | 5 | |
| SD | 20 (26.3) | 15 | 5 | |
| PD | 35 (46) | 8 | 27 | |
| NE | 2 (2.7) | 1 | 1 | |
n: number of patients; EGFR: epidermal growth factor receptor, PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluated. The significant p values are in bold.